Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study
Ionis Pharmaceuticals plans a 2026 FDA submission for zilganersen as a treatment for Alexander disease,…
Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study
Ionis Pharmaceuticals plans a 2026 FDA submission for zilganersen as a treatment for Alexander disease, an ultra-rare inherited neurological disorder. The antisense oligonucleotide developer has been moving toward commercializing drugs on its own rather than seeking partners. The post Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study appeared…
Extending Care Beyond the Hospital Walls
Fighting cancer is hard enough. Everyone deserves to heal in a clean, peaceful space. How one Crothall team is bringing comfort and control to patients in treatment When you’re in the middle of treatment for gynecologic cancer, even simple things like cleaning your home or apartment can feel impossible. “Because I was mentally foggy from…
Nudges, Not Information, For Engagement And Adoption
Successful healthcare innovators harness behavioral science to achieve adoption and behavior change. The post Nudges, Not Information, For Engagement And Adoption appeared first on MedCity News.
From Products to Services: How Medical Device Companies Miss $100M+ Opportunities
As trends around expanded decision-making ecosystems, consumer empowerment, data and intelligence, and economic uncertainty become everyday realities, the need for medical device companies to rethink and expand their business models becomes more urgent. The post From Products to Services: How Medical Device Companies Miss $100M+ Opportunities appeared first on MedCity News.
From Products to Services: How Medical Device Companies Miss $100M+ Opportunities
As trends around expanded decision-making ecosystems, consumer empowerment, data and intelligence, and economic uncertainty become everyday realities, the need for medical device companies to rethink and expand their business models becomes more urgent. The post From Products to Services: How Medical Device Companies Miss $100M+ Opportunities appeared first on MedCity News.
RCM Outsourcing: Balancing Human Expertise & Smart Technology
[Sponsored] Greenway Health blends smart technology with human expertise to elevate revenue cycle. The post RCM Outsourcing: Balancing Human Expertise & Smart Technology appeared first on MedCity News.
Pharmacy as the Front Line of the Consumer Experience Revolution
[Sponsored] In an interview, Abarca President and COO Adriana Ramirez shared why the future of healthcare must prioritize the human experience, powered by technology. The post Pharmacy as the Front Line of the Consumer Experience Revolution appeared first on MedCity News.
As the Trump Administration and States Push Health Data Sharing, Familiar Challenges Surface
The Northeast Valley Health Corp. in Los Angeles County could be a poster child for the benefits of sharing health data electronically. Through a data network connecting its records system with other providers, the health center receives not just X-ray and lab results but real-time alerts when hospitals on the network admit or discharge its…
New Bereavement Cost Calculator shows that grief is expensive
by EMMA PAYNE Grief is expensive. In addition to the significant human impacts, research shows that bereavement leads to a 20%-30% increase in health care utilization. Grief is also common. While we may not like to talk about it, 37% of Americans are grieving a recent death. The U.S. averaged 3.26 million deaths per year…
‘Sick to My Stomach’: Trump Distorts Facts on Autism, Tylenol, and Vaccines, Scientists Say
Ann Bauer, a researcher who studies Tylenol and autism, felt queasy with anxiety in the weeks leading up to the White House’s much-anticipated autism announcement. In August, Bauer and her colleagues published an analysis of 46 previous studies on Tylenol, autism, and attention-deficit/hyperactivity disorder. Many found no link between the drug and the conditions, while…
